Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Irene Robinson

  • Home
  • Author: Irene Robinson

REMD-477 top line results highlight the benefits of adjunct therapies in Type 1 Diabetes

REMD Biotherapeutics recently announced the top-line results of its Phase II study of volagidemab, which aimed to determine whether volagidemab could decrease daily insulin requirements and improve glycemic control in Type 1 Diabetes (T1D patients). These results show the promise of adjunct therapeutics, as their potential impacts on lowering blood glucose levels, reducing patient insulin […]
Read more

Remote patient monitoring will continue to transform healthcare delivery and clinical trials in 2021

Ongoing COVID-19 lockdowns and requirements of social distancing have swiftly pushed healthcare provision and patient monitoring towards remote options. Even though remote patient monitoring (RPM) was already being used before the start of the pandemic, the uptake of the technology was relatively low, primarily used to ensure better post-acute care and management of chronic conditions, such as diabetes. However, […]
Read more

Global rheumatoid arthritis market set to reach $29.1bn by 2029

The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 1.0%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2029’, reveals that although the […]
Read more

Quidel’s COVID-19 antigen test likely to be of interest to low-income countries

Following Quidel’s third Food and Drug Administration’s (FDA) emergency use authorization (EUA) of a COVID-19 antigen test; Dara Lo, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “Quidel’s COVID-19 test could be of great interest to low-income countries that typically cannot afford population-wide testing due to the cost-effectiveness of […]
Read more

TAVR market projected to reach nearly $5bn in US alone by 2030 as treatable populations continue to be added

While transcatheter aortic valve replacement (TAVR) procedures are historically reserved for elderly population, these devices are increasingly being used in younger and younger patients as they provide reduced hospital stay and recovery time. Therefore, due to the growing treatable populations for these devices, leading data and analytics company GlobalData predicts that the TAVR market may […]
Read more

49% of clinical trial disruption due to slow enrollment

As of November 30, 2020, the top reason for disrupted clinical trials is slow enrollment, which is causing delays in 49% of trials. The other main reasons for disruptions are enrollment suspension at 35%, and delayed initiation at 16%, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, Pharma Analyst at GlobalData, comments: “Although suspended […]
Read more

Renal denervation market demonstrates tremendous opportunity following FDA breakthrough device designation

SoniVie and ReCor Medical both recently received US Food and Drug Administration (FDA) breakthrough device designation for their TIVUS and Paradise renal denervation systems. With few manufacturers in the field and a market opportunity of almost 10 million hypertensive patients each year, the breakthrough designation puts ReCor Medical and SoniVie far ahead of larger manufacturers […]
Read more

NovoNordisk’s Rybelsus a game changer in T2D but may face a tough road ahead as it strides into Alzheimer’s space

NovoNordisk’s decision to investigate its recently launched Type 2 Diabetes (T2D) drug Rybelsus (semaglutide) in a pivotal Phase IIIa study of patients with early Alzheimer‘s disease may allow the company to secure its position in yet another lucrative market. However, while this drug will benefit from being the first-to-market oral GLP-1RA in T2D space and capture a […]
Read more

Surge period expected for $590m ERCP & PTC devices market but this will not offset COVID-19 revenue loss

Currently expected to be valued at $590m by the end of 2020, the global endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography (PTC) devices market is anticipated to grow at a compound annual growth rate (CAGR) of 3.5 despite the negative impact of COVID-19, as these devices are necessary to resolve obstructions of the pancreatic and […]
Read more

COVID-19 deals boost South Korea’s pharmaceutical industry growth

South Korea’s pharmaceutical sector is becoming increasingly innovative and attractive to foreign investment only 18 months into the government’s $1.7bn five-year biotech plan. The country’s pharmaceutical industry is now poised to grow further due to its preparations to manufacture large amounts of COVID-19 vaccines for domestic and foreign markets, says GlobalData, a leading data and […]
Read more

AbbVie’s Rinvoq tops defending champion Dupixent in atopic dermatitis

The recently demonstrated superiority of AbbVie’s Rinvoq (upadacitinib) versus Regeneron and Sanofi’s Dupixent (dupilumab) across primary and all secondary endpoints in the Phase IIIb Heads Up study may well showcase its potential to usurp Dupixent as the gold standard of atopic dermatitis (AD) therapy, but it is the speed of which the efficacy became evident in patients that shows the drug’s real promise, says GlobalData, a leading data and […]
Read more
1 2 3 4 … 15